Pharmacokinetics of alpha-dihydroergocryptine in rats after intravenous and oral administration.
The pharmacokinetic properties of alpha-dihydroergocryptine methanesulphonate (alpha-DHEK, CAS 19467-62-0) were investigated in rat using a radioimmunoassay technique for nonmetabolized drug. alpha-DHEK, intravenously administered at the dose of 6 mg/kg, showed a plasma profile according to an open 3-compartment pharmacokinetic model with a long half-life (about 7.56 h). The kinetics of alpha-DHEK after oral administration (6 mg/kg) showed two peaks; the second peak at 8 h was probably due to an enterohepatic cycle. The disposition of alpha-DHEK consisted in a fast absorption and a slow elimination (t1/2el about 6.78 h). The alpha-DHEK was largely metabolized as results from the complex metabolite profile in body fluids and from very low urinary elimination of unchanged drug.
Grognet
J M
JM
Department de Recherche en Imagerie, Pharmacologie et Physiologie, Centre d'Etudes Nucléaires de Saclay, Gif-sur-Yvette, France.
Istin
M
M
Zanotti
A
A
Mailland
F
F
Coppi
G
G
D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D004088:Dihydroergotoxine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006207:Half-Life; D007275:Injections, Intravenous; D008297:Male; D008954:Models, Biological; D011863:Radioimmunoassay; D051381:Rats
D004088:Dihydroergotoxine